我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
3
批准总数
监管机构
2
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
NMPA
National Medical Products Administration
1
FDA
Food and Drug Administration
- Real-world data shows belumosudil is often used in combination after multiple prior therapies for chronic graft-versus-host disease (cGVHD). - A retrospective study in Germany and Switzerland found a 42% overall response rate in patients with advanced cGVHD treated with belumosudil. - Belumosudil demonstrated a steroid-sparing effect and manageable safety profile in patients with severe cGVHD. - The ROCK2 inhibitor shows potential in earlier lines of cGVHD therapy, warranting further investigation in prospective trials.
